Nicolás Triantafilo C. (@nico30f) header
Nicolás Triantafilo C. (@nico30f) profile picture

Nicolás Triantafilo C.

@nico30f

Hematólogo. Linfomas y Leucemia Linfocítica Crónica. #LEx

lexmeet.org
Joined August 2018
  • Tweets336
  • Following96
  • Followers340
41Media
Photo by Nicolás Triantafilo C. (@nico30f)Photo by Nicolás Triantafilo C. (@nico30f)Photo by Nicolás Triantafilo C. (@nico30f)Photo by Nicolás Triantafilo C. (@nico30f)Photo by Nicolás Triantafilo C. (@nico30f)Photo by Nicolás Triantafilo C. (@nico30f)Photo by Nicolás Triantafilo C. (@nico30f)Photo by Nicolás Triantafilo C. (@nico30f)Photo by Nicolás Triantafilo C. (@nico30f)Photo by Nicolás Triantafilo C. (@nico30f)
Nicolás Triantafilo C. retweeted
Breno Moreno de Gusmão (@morenodegusmao) profile picture
Breno Moreno de Gusmão
@morenodegusmaoNov 12
Sepsis complicated 6.2% of CAR-T hospitalizations in the US (2017-2022) and changed everything: in-hospital mortality 28.7% vs 1.1% (aOR 33.96), plus more organ failure and thrombohemorrhagic events. Infection prevention is not optional. #mmsm doi.org/10.1016/j.jtct.2026.…
3
7
479
Nicolás Triantafilo C. retweeted
British Journal of Haematology (@BrJHaem) profile picture
British Journal of Haematology@BrJHaemNov 11
LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma buff.ly/nJ1dh3x
Image from British Journal of Haematology (@BrJHaem)
1
4
4
670
Nicolás Triantafilo C. retweeted
Mostafa Faisal (@MostafaFaisal14) profile picture
Mostafa Faisal@MostafaFaisal14Nov 10
Clinical characteristics, treatment, and long-term outcomes in 987 patients with splenic marginal zone lymphoma to inform treatment and surveillance strategies | Blood Cancer Journal share.google/Q8BisVMoUfXiMaC…

Clinical characteristics, treatment, and long-term outcomes in 987 patients with splenic marginal...

Blood Cancer Journal - Clinical characteristics, treatment, and long-term outcomes in 987 patients with splenic marginal zone lymphoma to inform treatment and surveillance strategies

nature.com
1
1
8
859
Nicolás Triantafilo C. retweeted
Mostafa Faisal (@MostafaFaisal14) profile picture
Mostafa Faisal@MostafaFaisal14Nov 10
Metabolic tumor volume trajectory during bridging and association with outcomes after CAR T infusion in large B-cell lymphoma | Bone Marrow Transplantation share.google/btBkQ427BuMJOnM…
Metabolic tumor volume trajectory during bridging and association with outcomes after CAR T...

Metabolic tumor volume trajectory during bridging and association with outcomes after CAR T...

Bone Marrow Transplantation - Metabolic tumor volume trajectory during bridging and association with outcomes after CAR T infusion in large B-cell lymphoma

nature.com
3
13
1,125
Nicolás Triantafilo C. retweeted
Blood Journals Portfolio (@BloodPortfolio) profile picture
Blood Journals Portfolio@BloodPortfolioNov 8
Changes in muscle and fat distribution occur early in treatment highlighting the need for interventions to stabilize body composition. Patients with a higher volume of disease are more likely to experience certain side effects such as nerve pain. ow.ly/JWeb5104eB5
Image from Blood Journals Portfolio (@BloodPortfolio)
1
4
13
1,695
Nicolás Triantafilo C. retweeted
Dr. Thomas Ichim (@exosome) profile picture
Dr. Thomas Ichim
@exosomeNov 8
CAR-NK cells engineered to express IL-15 produced responses in 8 of 11 patients with refractory lymphoma or leukemia, including 7 complete responses. No cytokine release syndrome, neurotoxicity or graft-versus-host disease was observed. doi.org/10.1056/NEJMoa191060… this is why I love $IBRX and #anktiva
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors | NEJM

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors | NEJM

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of ...

nejm.org
4
15
1
101
4,691
Nicolás Triantafilo C. retweeted
Mostafa Faisal (@MostafaFaisal14) profile picture
Mostafa Faisal@MostafaFaisal14Nov 7
Incidence and risk factors for hypogammaglobulinemia after CD19 CAR T-cell therapy ashpublications.org/bloodict…
Incidence and risk factors for hypogammaglobulinemia after CD19 CAR T-cell therapy

Incidence and risk factors for hypogammaglobulinemia after CD19 CAR T-cell therapy

Key PointsSerum IgG levels declined after CAR-T infusion, reaching a nadir at 9 months, and remaining suppressed for >2 years after infusion.Older age,

ashpublications.org
1
2
13
918
Nicolás Triantafilo C. retweeted
Blood Journals Portfolio (@BloodPortfolio) profile picture
Blood Journals Portfolio@BloodPortfolioNov 6
CMV reactivation is common after CAR T-cell therapy for #LBCL, including in the 2L setting. Corticosteroid exposure is a major risk factor for CMV reactivation. Read in Blood ICT: ow.ly/tT205103NCK
Image from Blood Journals Portfolio (@BloodPortfolio)
13
2
37
3,492
Nicolás Triantafilo C. retweeted
Lymphoma Hub (@lymphomahub) profile picture
Lymphoma Hub
@lymphomahubNov 5
New publication 📝 Results from a phase II trial, published in @BloodPortfolio, show that glofitamab + pola-R-CHP achieved a 95% CR rate in patients with newly diagnosed DLBCL or HGBCL. Learn more about aggressive B-cell lymphomas: bit.ly/4aCi7Xu #DLBCL #Lymphoma #lymsm #MedNews #MedEd
Image from Lymphoma Hub (@lymphomahub)
1
4
6
645
Nicolás Triantafilo C. retweeted
Mostafa Faisal (@MostafaFaisal14) profile picture
Mostafa Faisal@MostafaFaisal14Nov 4
Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma aacrjournals.org/bloodcancer…
Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large...

Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large...

Multiomic profiling identifies reduced tumor CD19 expression as a determinant of inferior outcomes of CD19 CAR T-cell therapy in large B-cell lymphoma and reveals distinct patterns of resistance.

aacrjournals.org
2
7
23
1,643
Nicolás Triantafilo C. retweeted
Mostafa Faisal (@MostafaFaisal14) profile picture
Mostafa Faisal@MostafaFaisal14Nov 4
Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study aacrjournals.org/bloodcancer…
Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study

Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study

Glofitamab-based therapy produced high response rates and durable disease control in both primary and secondary relapsed or refractory CNS lymphoma, supporting prospective evaluation of bispecific...

aacrjournals.org
1
8
1
27
2,784
Nicolás Triantafilo C. retweeted
Ajay Major, MD, MBA (@majorajay) profile picture
Ajay Major, MD, MBA
@majorajayNov 2
Excited to share our new @BloodPortfolio manuscript comparing CAR-T vs BsAb in R/R FL. In addition to comparing survival, we also studied "time toxicity," or how much time patients spend physically interacting with the healthcare system. #lymsm 🧵 ashpublications.org/bloodadv…
Image from Ajay Major, MD, MBA (@majorajay)
3
19
3
73
5,020
Nicolás Triantafilo C. retweeted
Uriel Suárez (@UsuarezMD) profile picture
Uriel Suárez
@UsuarezMDOct 29
ashpublications.org/bloodadv… @alberto_guijosa @DanaFarber
Impact of initial dosing and subsequent dose reduction of zanubrutinib in patients with Waldenström...

Impact of initial dosing and subsequent dose reduction of zanubrutinib in patients with Waldenström...

Key Points. Standard-dose zanubrutinib (160 mg twice-daily or 320 mg daily) yields equivalent efficacy in WM; sub-standard initiation worsens outcomesToxic

ashpublications.org
2
17
1,637
Nicolás Triantafilo C. retweeted
Uriel Suárez (@UsuarezMD) profile picture
Uriel Suárez
@UsuarezMDOct 29
Frontline Bruton tyrosine kinase inhibitors are associated with improved response and PFS in primary CNS lymphoma ashpublications.org/bloodadv…
Frontline Bruton tyrosine kinase inhibitors are associated with improved response and PFS in...

Frontline Bruton tyrosine kinase inhibitors are associated with improved response and PFS in...

Key Points. Frontline BTK inhibitors are associated with favorable progression-free survival and complete response rates in primary CNS lymphoma.Performanc

ashpublications.org
14
33
2,042
Nicolás Triantafilo C. retweeted
Uriel Suárez (@UsuarezMD) profile picture
Uriel Suárez
@UsuarezMDOct 29
Safety and efficacy of port use for CAR T-cell infusion in large B-cell lymphoma nature.com/articles/s41408-0…
Safety and efficacy of port use for CAR T-cell infusion in large B-cell lymphoma

Safety and efficacy of port use for CAR T-cell infusion in large B-cell lymphoma

Blood Cancer Journal - Safety and efficacy of port use for CAR T-cell infusion in large B-cell lymphoma

nature.com
4
1
10
2,433
Nicolás Triantafilo C. retweeted
Uriel Suárez (@UsuarezMD) profile picture
Uriel Suárez
@UsuarezMDOct 29
Omission of Radiation Therapy is Associated with Inferior Disease Control in High Risk Early-Stage Hodgkin Lymphoma ashpublications.org/bloodadv…
Omission of Radiation Therapy is Associated with Inferior Disease Control in High Risk Early-Stage...

Omission of Radiation Therapy is Associated with Inferior Disease Control in High Risk Early-Stage...

Key Points. CMT confers significantly superior PFS in bulky or iPET-positive (DS≥4) early-stage HL, supporting consolidative RT in high-risk patients.iPET-

ashpublications.org
2
6
1
34
3,818
Nicolás Triantafilo C. retweeted
Mazyar Shadman, MD MPH (@mshadman) profile picture
Mazyar Shadman, MD MPH
@mshadmanOct 29
Just published in @BloodAdvances! "CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma in the United States" Only ~15% of patients receive CAR T. We need to continue generating data, raising awareness, and improving access and utilization. ashpublications.org/bloodadv… Thanks to all the authors and collaborators at @bmsnews @lymphomaphilia @KrishPatelMD @LNastoupilMD @mana1981
CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma...

CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma...

Key Points. Real-world data showed that fewer than 2 in 10 patients with relapsed/refractory large B-cell lymphoma had access to CAR T-cell therapyLimited

ashpublications.org
1
12
28
1,789
Nicolás Triantafilo C. retweeted
GELTAMO (@geltamo) profile picture
GELTAMO
@geltamoOct 27
🆕Nueva publicación @geltamo EZH2 mutation status predicts inferior outcomes after bendamustine‐based immunochemotherapy in frontline follicular lymphoma: A GELTAMO multicenter validation study 2026 - HemaSphere onlinelibrary.wiley.com/doi/… @crolaper
Image from GELTAMO (@geltamo)
8
16
1,398
Nicolás Triantafilo C. retweeted
Graham Collins (@graham74GC) profile picture
Graham Collins@graham74GCOct 27
Great to see a randomised study of CAR-T (zamto-cel) v R-GemOx, transplant ineligible relapsed DLBCL. Whilst there was EFS & PFS benefit for zamto-cel, OS the same and no obvious plateau on PFS curve. Tox of zamto is modest - all grade ICANs 11%. #lymsm thelancet.com/journals/lanon…
Image from Graham Collins (@graham74GC)
13
51
3,773
Nicolás Triantafilo C. retweeted
GELTAMO (@geltamo) profile picture
GELTAMO
@geltamoOct 26
Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma ashpublications.org/bloodadv… @arivasdelgado
6
24
1,667
Load more